

Attorney Docket No.: DC0266US.NP  
Inventors: Kitareewan, et al.  
Serial No.: 10/564,070  
Filing Date: March 3, 2006  
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A method for identifying an agent which destabilizes lysosomes to increase oncogenic or aberrant protein degradation comprising contacting a lysosome or a cell containing a lysosome with an agent and detecting whether said agent destabilizes the lysosome thereby increasing oncogenic or aberrant protein degradation.

Claim 2 (original): An agent identified by the method of claim 1.

Claim 3 (original): The agent of claim 2, wherein said agent comprises chloroquine or a derivatives, analog, or enantiomer thereof.

Claim 4 (original): A method for increasing oncogenic or aberrant protein degradation in cells comprising contacting cell with an effective amount of an agent which destabilizes lysosomes thereby increasing the degradation of oncogenic or aberrant proteins.

Claim 5 (original): The method of claim 4, wherein the agent comprises arsenic, all-*trans*-retinoic acid, chloroquine or a derivative or a combination thereof.

Attorney Docket No.:	DC0266US.NP
Inventors:	Kitareewan, et al.
Serial No.:	10/564,070
Filing Date:	March 3, 2006
Page 3	

Claim 6 (original): A method for treating a disease or condition associated with an oncogenic or aberrant protein comprising administering to a patient in need of treatment an effective amount of an agent which destabilizes lysosomes so that oncogenic or aberrant proteins degradation is increased thereby treating the disease or condition associated with the oncogenic or aberrant protein.

Claim 7 (original): The method of claim 6, wherein the agent comprises arsenic, all-*trans*-retinoic, chloroquine or a derivative or combination thereof.